You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

Citation Tools

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Hecht M, Gostian AO, Eckstein M, et al
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
Journal for ImmunoTherapy of Cancer 2020;8:e001378. doi: 10.1136/jitc-2020-001378